Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. A short Q&A session will follow.įor more information about the event and to register for free, visit: About Novamind Conforti will deliver a presentation to update investors on the Company's rapidly growing network of psychiatry clinics and clinical research sites focused on psychedelic medicine. ![]() Novamind's CEO and Director, Yaron Conforti, will join a panel of industry leaders for a discussion titled, " Addressing Mental Health through Emerging Therapies" on Thursday, September 30 at 12:35 PM EST.įollowing the panel, from 1:15 PM to 1:30 PM EST, Mr. (CSE: NM) (OTCQB: NVMDF) (FSE: HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, will participate in the Benzinga Small Cap Healthcare Conference taking place virtually on September 29-30, 2021. Novamind to Present at Benzinga Healthcare Conference Novamind to be featured in panel discussion on the disruptive potential of psychedelic medicine in mental healthcare Company Overview Our Team Our Commitment Success Stories Upcoming Events Careers.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |